MKMahmoud A. Khaimi

Mahmoud A. Khaimi

*This is an algorithmically generated author record based on publicly available information.

Mahmoud A. Khaimi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Ben J. Harvey

    Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, USA

    2 shared publications
  • Evan J. Allan

    Dean McGee Eye Institute †University of Oklahoma College of Medicine ‡Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    2 shared publications
  • Joshua M. Jones

    Disclosure: The authors declare no conflict of interest

    2 shared publications
  • Kai Ding

    Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

    2 shared publications
  • Annah Baykal

    Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, USA

    1 shared publication
  • Christian Leal

    Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, USA

    1 shared publication

Latest Publications

  • Canaloplasty via an ab-interno approach in primary open-angle glaucoma: Results from a large case series

    by Mahmoud A. Khaimi

    To evaluate the effectiveness and safety of ab-interno canaloplasty using the iTrack microcatheter in patients with primary open-angle glaucoma (POAG). This retrospective, single-center case series included eyes with POAG treated with iTrack ab-interno canaloplasty (Nova Eye Medical, USA), performed either as a standalone procedure or combined with phacoemulsification, with a minimum follow-up of 12 months. Primary outcomes were changes in IOP and number of glaucoma medications. Secondary outcomes included visual acuity (VA), visual field (VF) mean deviation (MD), complications, need for additional glaucoma surgery, and surgical success (as defined by American Academy of Ophthalmology [AAO] criteria). Subgroup analyses were conducted based on disease severity, baseline IOP (≤ 18 mmHg vs. > 18 mmHg), and preoperative medication use (0-4). Both standalone (n = 167) and combined (n = 364) procedures achieved significant reductions in IOP and medication use (p < 0.001). At the last follow-up (mean: 20.4 ± 7.7 months), mean IOP was reduced by 3.29 ± 6.0 mmHg in the combined group (from 17.5 ± 5.8 to 14.2 ± 3.8 mmHg) and by 4.50 ± 6.1 mmHg in the standalone group (from 20.2 ± 6.0 to 15.7 ± 4.3 mmHg), with the standalone group showing a significantly greater absolute IOP reduction (p = 0.025). Medication burden was reduced by 1.05 ± 1.06 medications in the combined group and by 0.84 ± 1.15 in the standalone group (p = 0.032). Subgroup analyses confirmed significant IOP and/or medication reductions across all strata, with greater relative benefits in eyes with uncontrolled baseline IOP (> 18 mmHg). Surgical success was 64% in combined and 47% in standalone procedures; success was 75% and 46% in eyes with uncontrolled and controlled baseline IOP. Intraoperative complications were infrequent (1.6%), and 13.1% of eyes required additional glaucoma surgery during follow-up. Ab-interno canaloplasty using the iTrack microcatheter, whether as a standalone procedure or combined with phacoemulsification, resulted in sustained reductions in IOP and medication use, with a low rate of complications. These outcomes were consistent across varying levels of disease severity and baseline IOP, with the most pronounced benefits observed in eyes with elevated preoperative IOP.

  • Open Access

    Canaloplasty via an ab-interno surgical technique in patients with primary angle closure glaucoma

    by Mahmoud A. Khaimi, Ben J. Harvey, Jessica Hsueh, Christian Leal, Annah Baykal

    Purpose To investigate the clinical outcomes of canaloplasty performed with the iTrack microcatheter (Nova Eye Medical, Fremont, USA) as a standalone procedure and in combination with phacoemulsification in patients with primary angle-closure glaucoma (PACG). Methods A single-center, retrospective case series of eyes undergoing canaloplasty via an ab-interno technique with a diagnosis of PACG based on gonioscopy findings (Shaffer grading). Patients were excluded if they had previously undergone a glaucoma procedure other than Laser Peripheral Iridotomy (LPI). Eyes were grouped by glaucoma severity based on mean deviation preoperative values. Outcome measures included intraocular pressure (IOP) and number of glaucoma medications. Results Sixty eyes (9 canaloplasty-standalone, pseudophakic, and 51 canaloplasty + phaco) were eligible. The mean baseline IOP was 21.9 ± 7.3 mmHg and number of glaucoma medications was 1.95 ± 1.4. At the latest follow-up (mean 26 ± 9.2 months), they were reduced to 14.6 ± 3.7 mmHg (p < 0.001) and 0.96 ± 1.2 (p < 0.001). IOP reduction was statistically significant when canaloplasty was performed as a standalone procedure (baseline 22.78 ± 6.72 vs 17.00 ± 3.42 at the latest follow-up) or combined with phacoemulsification (21.75 ± 7.43 vs 14.21 ± 3.66) or if canaloplasty was performed in mild (20.8 ± 4.93 vs 15.5 ± 3.63), moderate (21.9 ± 8.58 vs 13.9 ± 3.90) or severe (23.5 ± 11.3 vs 12.4 ± 3.20) glaucoma eyes, with no difference between the groups postoperatively. Medication reduction was significant when canaloplasty was performed in combination with phacoemulsification and in mild glaucoma eyes. No serious intraoperative or postoperative complications were reported. Conclusion Canaloplasty via an ab-interno surgical technique, performed as standalone or combined with phacoemulsification, is a safe and clinically effective treatment in primary angle closure glaucoma patients up to 2 years.


  • Open Access

    Consistency in Standalone Canaloplasty Outcomes Using the iTrack Microcatheter

    by Mahmoud Khaimi, Norbert Koerber, Simon Ondrejka, Mark J Gallardo

    Purpose: To study the consistency in outcomes of standalone canaloplasty performed via an ab-interno surgical technique in reducing intraocular pressure (IOP) and number of medications in uncontrolled open-angle glaucoma (OAG) eyes over a 12-month period. Methods: This retrospective multicenter case series included patients who underwent standalone canaloplasty via an ab-interno surgical technique using the iTrack microcatheter (Nova Eye, Inc., Fremont, USA) and had preoperative uncontrolled OAG (IOP≥ 18mmHg) along with no previous glaucoma surgery. The iTrack microcatheter is used to circumnavigate 360° and viscodilate Schlemm’s canal. Consistency of IOP and medications reduction on an eye-by-eye basis were evaluated to understand the outcomes in each single eye. Results: Sixty-four eyes of 60 patients (age 71.5± 13.4 years) were included. Six eyes (9%) that underwent additional glaucoma surgery were considered a failure and were subsequently excluded from analysis. At 12 months, IOP was reduced in 57 of the 58 (89%) remaining eyes; one eye had the same IOP with a reduced number of medications. Of the 57/58 eyes with a reduced IOP: 44 eyes (69%) required fewer medications; 12 eyes (19%) required the same number of medications. Of these 58 eyes, 78% of eyes had a ≥ 20% reduction in IOP compared to baseline; 69% eyes had a postoperative IOP ≤ 15 mmHg, and 86% eyes ≤ 18 mmHg at 12 months. Forty percent of the eyes were medication-free at 12 months compared to none at baseline. Conclusion: Canaloplasty performed via an ab-interno surgical technique as a standalone procedure consistently reduced IOP and glaucoma medications in almost all eyes.


  • Surgical Management of Intraocular Pressure With Ab Interno Canaloplasty in Postkeratoplasty Patients: 12-Month Results

    by Kamran M. Riaz, Mohsain S. Gill, David A. Murphy, Kai Ding, Mahmoud A. Khaimi

    Purpose: The purpose of this study was to report clinical outcomes of ab interno canaloplasty (ABiC) with the iTrack microcatheter (Nova Eye Medical, Fremont, CA) for surgical management of intraocular pressure (IOP) in postkeratoplasty patients. Methods: This study was a single-center retrospective case series of postkeratoplasty eyes undergoing ABiC. Efficacy was evaluated based on graft survivability and mean reduction in IOP at 12 months postoperatively. Secondary end points consisted of visual acuity outcomes, number of topical hypotensive medications, and rate of complications. Results: ABiC was successfully performed in 17 eyes after keratoplasty (8 penetrating keratoplasty, 6 DSAEK, 2 penetrating keratoplasty + DSAEK, and 1 DMEK) with elevated IOP refractory to topical hypotensive medications. The baseline mean IOP was 26.2 ± 8.4 mm Hg and reduced significantly to 15.0 ± 4.21 mm Hg at 6 months and 13.0 ± 2.99 mm Hg at 12 months (P < 0.005). The best-corrected visual acuity improved from 0.61 ± 0.55 logMAR at baseline to 0.47 ± 0.59 and 0.49 ± 0.64 at 6 and 12 months, respectively, following ABiC (not statistically significant: P = 0.6769). The baseline mean number of topical hypotensive medications was 3.7 ± 1.8 and reduced to 2.7 ± 1.4 and 2.9 ± 1.3 at 6 and 12 months, respectively (P = 0.096). One patient developed a hyphema which required anterior chamber washout. One patient required additional glaucoma surgery 19 months after ABiC. No patients experienced graft failure. Conclusions: ABiC is a clinically safe and effective treatment that can be performed in postkeratoplasty patients to reduce IOP for at least 1 year without any significant complications.


  • Open Access

    Long-term medication reduction in controlled glaucoma with iTrack ab-interno canaloplasty as a standalone procedure and combined with cataract surgery

    by Mahmoud A. Khaimi

    To evaluate the long-term effectiveness of iTrack (Nova Eye Medical, Fremont, USA) ab-interno canaloplasty performed as a standalone procedure, or combined with cataract surgery, in reducing antiglaucoma medication dependence and maintaining intraocular pressure within target range in patients with controlled primary open-angle glaucoma. This is a retrospective, single-center, case series study of patients who underwent iTrack ab-interno canaloplasty as a standalone procedure (n = 34) or in combination with cataract surgery (n = 11). Eyes with controlled mild or moderate glaucoma (intraocular pressure ⩽17 mmHg) were included; those with prior glaucoma surgeries were excluded. The primary outcome was the mean reduction in glaucoma medication and the secondary outcome was the maintenance of controlled intraocular pressure postoperatively. A total of 35 patients (45 eyes) with a mean age of 73 ± 9.7 years were included in the study. For all eyes, a significant decrease (61%) in the mean number of medications was seen at 36 months (1.89 ± 0.93 versus 0.60 ± 0.82; p < 0.001), with 56% (14/25) of eyes medication free. No significant difference was observed in the reduction of medication use whether iTrack was performed with or without cataract surgery at 12 and 36 months. Mean baseline intraocular pressure of 14.42 ± 2.2 mmHg for all eyes was maintained at the 12-, 24-, and 36-month follow-up visits (14.6 ± 3.65, 15.06 ± 2.26, and 14.19 ± 2.91, respectively), with no significant difference between the two groups (p = 0.08). The iTrack ab-interno canaloplasty significantly reduced medication dependency and maintained intraocular pressure within target range in patients with controlled mild or moderate primary open-angle glaucoma, while showing a good safety profile, both as a standalone procedure or in combination with cataract surgery.


  • Evaluation of Spin in the Abstracts of Systematic Reviews and Meta-analyses of Treatments for Glaucoma

    by Ochije Bs Okonya, Elaine Bs Lai, Ryan Bs Ottwell, Mostafa Bs Khattab, Wade Bs Arthur, Mahmoud A. Khaimi, Drew N. Mls Wright, Micah Hartwell, Matt Vassar

    Purpose: Spin—the misrepresentation of the study’s actual findings—carries the ability to distort a reader’s perception of a treatments’ full benefits and risks. Recent studies have suggested that spin is common in abstracts of randomized controlled trials and systematic reviews focused on treatments for a variety of medical disorders. Therefore, our primary objective was to evaluate the prevalence of spin in the abstracts of systematic reviews and meta-analyses related to glaucoma treatments. We further assessed whether specific study characteristics were associated with spin, including the methodological quality of a study. Patients and Methods: We used a cross-sectional study design searching MEDLINE and Embase databases all for systematic reviews and meta-analyses focused on glaucoma treatments. Each abstract was assessed for the 9 most severe—severity determined by the likelihood of distorting a reader’s perception—types of spin that occur in systematic review abstracts. The screening and data extraction was performed in a duplicate, masked fashion. The methodological quality of each review was assessed using the A MeaSurement Tool to Assess Systematic Reviews (AMSTAR-2) instrument. To evaluate relationships between spin, AMSTAR-2 appraisals, and other study characteristics, we used unadjusted odds ratios and the Fisher exact test. Results: Only 3 of the 102 abstracts contained spin, with spin type 5 being the most prevalent. No abstracts contained spin types 1, 2, 3, 4, 6, or 8, and no association was found between the presence of spin in an abstract and any particular study characteristic. Using the AMSTAR-2 quality appraisal instrument, 35 (34.3%) of the studies received a methodological quality rating as high, 42 (41.2%) as moderate, 11 (10.8%) as low, and 14 (13.7%) as critically low. Conclusions: We found that spin is present in only a small proportion of systematic reviews and meta-analyses covering the treatment of glaucoma. In comparison to studies in other fields of medicine, ophthalmology appears to be a leader in publishing systematic reviews and meta-analyses with low rates of spin occurring in the


  • Open Access

    A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty

    by Mahmoud A Khaimi

    Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty. Methods: This was a retrospective medical chart review conducted at a single US center. Data were collected on patients with glaucoma who underwent canaloplasty with or without cataract surgery, and were prescribed LE suspension 0.5% postoperatively. Outcomes evaluated included postsurgical inflammation (anterior chamber [AC] cells and flare), intraocular pressure (IOP), number of IOP-lowering medications, and postsurgical complications. Results: Data were collected on 204 patients (262 eyes) with a mean (SD) age of 71.6 (11.3) years. The most frequent LE dosing regimens at day 1, week 1, and month 1 postsurgery were QID (92.3%; 241/261), TID (52.6%; 133/253), and QD (65.5%; 78/119), respectively. Inflammation (AC flare and cells), mostly mild, was noted in 33.2% (86/259) of eyes on postoperative day 1 and 8.6% (21/244) of eyes at month 1. Mean IOP and mean number of IOP-lowering medications were significantly reduced from baseline (PConclusion: These real-world data suggest that canaloplasty with or without cataract surgery managed postoperatively with LE suspension 0.5% is effective and safe in the glaucoma patient.


  • Open Access

    An Analysis of 3-Year Outcomes Following Canaloplasty for the Treatment of Open-Angle Glaucoma

    by Mahmoud A. Khaimi, Justin D. Dvorak, Kai Ding

    Purpose. To report 3-year results investigating the safety and efficacy of canaloplasty for open-angle glaucoma. Setting. University of Oklahoma, Dean McGee Eye Institute, Oklahoma, United States of America. Design. Nonrandomized single-center retrospective chart review. Methods. Adult open-angle glaucoma eyes underwent canaloplasty or combined cataract-canaloplasty surgery. A tensioning suture was placed into Schlemm’s canal in all eyes. Primary endpoints included the mean IOP and mean number of glaucoma medications at each follow-up visit. Secondary endpoints included visual acuity and surgical/postsurgical complications. Results. The study cohort included 277 eyes (mean age, 72.8 years). Overall, the mean baseline IOP of 19.7 mmHg was reduced to 14.3 mmHg,14.0 mmHg, and 15.2 mmHg at 1, 2, and 3 years, respectively (p<0.001). The average medicine use was reduced from 2.1 preoperatively to 0.4 at 12 months, and 0.5 and 0.6 at two and three years, respectively (p<0.001). The frequency of surgical and postsurgical complications was low with no serious adverse events recorded. Conclusion. Canaloplasty was safe and effective in achieving long-term IOP reductions and reduced dependence on antiglaucoma medications.


  • Outcomes of Bleb Revision With Mitomycin C After Ex-PRESS Shunt Surgery

    by Evan J. Allan, Joshua M. Jones, Kai Ding, Mahmoud A. Khaimi

    Investigate efficacy and safety of bleb revision using mitomycin C after Ex-PRESS shunt surgery. We performed chart reviews of 36 consecutive eyes from 34 patients with previous Ex-PRESS shunt surgery who underwent subsequent bleb revision with mitomycin C. The mean follow-up time was 13.5 months. The primary outcome measure was surgical success. Secondary outcomes included visual acuity, intraocular pressure, number of medications, and complications. Twenty-four eyes had open-angle glaucoma (61.1%). Mean time from Ex-PRESS to bleb revision was 8.8 months. Complete success rate for the immediate 3-month postoperative period was 94.4% and qualified success rate was 97.2%. Complete and qualified success rates for the entire follow-up period were 40% and 65.7%, respectively. Visual acuity remained stable throughout the study period, and at 1 year, average intraocular pressure was 14.7 mm Hg on an average of 1.7 medications. No major complications were reported. Bleb revision in eyes with an Ex-PRESS shunt is a safe and efficacious procedure. The surgical outcomes are within the range of published outcomes for bleb needling after trabeculectomy. Further research with larger sample size and longer follow-up is needed to confirm these results.


  • Efficacy of selective laser trabeculoplasty after canaloplasty

    by Ilya M Sluch, Mahmoud A Khaimi, Kai Ding, Steven R Sarkisian